RELATED APPLICATION

[0001] This application, claims priority from U.S. Provisional Application Serial No.

61/974,252, filed April 2, 2014, the entire disclosure of which is incorporated herein by this reference.

GOVERNMENT INTEREST

[0002] This invention was made with government support under grant number HI. 10901 awarded by the National Institutes of Health. The government has certain rights in the invention.

TECHNICAL FIELD

[0003] The presently-disclosed subject matter relates to cardiotonic steroid antagonists and methods of using the same. In particular, the presently-disclosed subject matter relates to cardiotonic steroid antagonists comprising a peptide that functions as a Src SH2 domain antagonist of cardiotonic steroids and methods of using that peptide antagonist for the treatment of Src-associated diseases, such as cancer and cardiovascular disease. BACKGROUND

[0004} Cardiotonic steroids are a group of compounds that bind to and inhibit Na/ -ATPase, a protein which is responsible for regulating ionic homeostasis. Newly emerging evidence suggests these compounds are synthesized in mammalian bodies and may regulate several important cellular processes in response to external stimulus. To date, however, the Na/K- ATPase still remains the only identified target for binding of cardiotonic steroids on a ceil surface (Prassas and Diamandis 2008),

[0005] Na/ -ATPase is an ion transporting protein that pumps Na ^: and K ^" ions across the membrane. Besides ion pumping, a large number of Na/K-ATPases in the cell membrane can also form a receptor complex for cardiotonic steroids by directly interacting wit Src kinase. Indeed, cardiotonic steroid binding can activate the bound Src kinase that in turn phosphoryiates multiple protein kinases, stimulates ROS (Reactive Oxygen Species) production, alters intracellular calcium concentrations and thereby affects cell growth, proliferation and survival (Xie and Ca$ 2003). Moreover, endogenous cardiotonic steroids have a well-described role in regulating cardiovascular and renal functions. In this aspect, the signaling function of a/ ~ ATPase is thought to be important as the circulating concentrations of endogenous cardiotonic steroids is extremely low and is unlikely to affect its ion pumping function. Deregulations in this signaling function results in cardiovascular as well as renal diseases and may also contribute to cancer cell growth. Therefore, there is a need for the de velopment of molecules that are

specifically targeted towards the inhibition of such cardiotonic steroid-mediated signal transduction (Bagrov, Shapiro et a.l. 2009).

[0006] Src kinase is a protein tyrosine kinase that is known to act as a mediator in many signaling pathways that regulate cellular properties. Deregulation of Src kinase is often associated with or known to be the causative agent for a variety of diseases including cancer and osteoporosis (Bolen, Veiiiette et al. 1987, Bromaon, Korkaya et si. 2004, Brunton, Avizrenyte et al. 2005). Currently, there are at least four Src kinase inhibitors (dasatinib, bosutinib, sarcatinib, and KXO} } under development for cancer therapeutics, f lowever, most of those inhibitors suffer from a lack of specificity, arid thus, there is also a need for the development of Src-based inhibitors that are more specific in nature.

[0007} With further respect to the Src kinase, Src kinase comprises of a number of domains - a kinase domain that functions in phosphor) dating other proteins and a SH2 and a SH3 domain that helps Src kinase to bind to signaling proteins and a unique region. I fact, Src kinase belongs to a large family of tyrosine kinases which share high degree of similarity in their kinase domain structure (Boggon and Eck 2004). As such, most inhibitors that are developed to target the Src kinase domain can also interact with other protein kinases nonspeeifieaily, which, i turn, results in the observed loss of specificity, in contrast, however, the SH2 domain which serves the critical function of targeting Src kinase to signaling complexes for mediating protein-protein interaction tends to be highly specific (Songyang, Shoeison et al 5993), and many intracellular signaling cascades, whose deregulation can cause diseases, rely on SH2 domain-mediated binding of Src kinase (Shvartsman, Donaldson et al. 2007), making the SH2 domain of Src a target for developing inhibitor molecules.

£0008] It is appreciated that SH2 domains recognize and bind preferably to phosphorykted tyrosine residues and the sequence surrounding the phosphotyrosine determines the specificity (Songyang and Cantley 2004). in tact, the selectivity for the tyrosine phosphorylation is so high that that residue is alone thought to confer about half of the binding energy. To da te though, most SH2 domain inhibitors are still under development in in vitro systems in order to increase their efficacy under physiological conditions (Kxaskousfcaya, Duodu et al. 2013). n this context. a Src SH2 domain-directed specific antagonist of cardiotonic stero ids would be bot h highly- desirable and beneficial as such an antagonist would he capable of: 1) antagonizing cardiotonic steroids; and 2) inhibiting Src-mediated signal transduction with a high level of selectivity.

SUMMARY

(0009| The presently-disclosed subject matter meets some or all of the above-identified needs, as will become evident to those of ordinary skill in the art after a study of information provided in thi document.

[0010j This Summary describes several embodiments of the presently-disclosed . subject matter, and in many cases lists variations and permutations of these embodiments. This

Summary is merely exemplary of the numerous and varied embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an

embodiment can typically exist with or without the feature(s) mentioned; likewise, those features can be applied to other embodiments of the presently-disclosed subject matter, whether listed in this Summary or not. To avoid excessive repetition, this Summary does not list or suggest all possible combinations of such features.

[0011 j The presently-disclosed subject matter includes cardiotonic steroid antagonists and methods of using the same. In particular, the presently-disclosed subject matter includes cardiotonic steroid antagonists that are comprised of a peptide that functions as a Src S 2 doma in antagonist of cardiotonic stero ids and methods of using that peptide antagonist for the treatment of Src-associated diseases, such as cancer and cardiovascular disease.

[001.2] in some embodiments of the presently-disclosed subject matter, a cardiotonic steroid antagonist is provided in the form of a non-natura!Jy occurring peptide. In some embodiments, the rion-natura!!y occurring peptide comprises a tyroshie-phosphoryiated fragment of the second cytoplasmic domain of a Na/K-ATPase a! subunit. In some embodiment, the non-naturally occurring peptide comprises the sequence of SEQ ID NO: 1. In some embodiments, the non- naturally occurring peptide comprises a eel! penetrating peptid operab!y linked to the peptide of SEQ ID NO: 1, such as, in certain embodiments, a HIV-TAT peptide, a penetratin peptide, a polyarginme peptide, a pep-1 peptide, and a transportm peptide, in some embodiments, the cell- penetrating pep tide operab!y l inked to the sequence of SEQ iD NO: I is a HIV-TAT peptide. In further embodiments, vectors are also provided that comprise a nucleic acid encoding a non- naturally occurring peptide having the sequence of SEQ ID NO; 1 operably linked to an

expression cassette for expression of the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO; 1,

[0013] Also provided, in some embodiments of the presently-disclosed subject matter, are pharmaceutical compositions comprising a non-naturally occurring peptide having the sequence of SEQ ID NO: 1 and a pharmacenticaUy-acceptable vehicle, carrier, or excipient. in some embodiments, such pharmaceutical compositions further comprise an additional therapeutic agent, such as, in some embodiments, a cheniotherapeutic agent, a toxin, an immunological response modifier, an enzyme, or a radioisotope. In some embodiments, the non-naturally occurring peptide is included in the composition in an amount sufficient to affect a cellular process selected from the group consisting of; antagonizing a cardiotonic steroid (CTS)-induced protein kinase cascade; upreguiating a CTS induced protein kinase cascade; Src inhibition; Src stimulation; Na/K-ATPase .mimic; Na/K-ATPase competitive inhibitor; Lyn inhibition; Lyn stimulation; ouabain antagonism; ouabain stimulation; ERKl/2 activation; ERKl/2 inhibition; membrane permeability by sodium ions; and membrane permeability by potassium ions, in som embodiments, the non-aaturaily occurfing peptide included in the composition binds to Src with an IC50 of less than about 10 μΜ.

j00!4j Further provided are methods of treating a Src -associated disease. In some

embodiments, methods of treating an Src -a ssociated d isease are provided that com prise administering an eftective amount of a non-nafuraliy occurring peptide comprising the sequence of S EQ ID NO: I to a subject in need thereof. In some embodiments, the Src-associated disease is selec ted from the group consisting of cancer, vascular disease, cardiovascular disease, tissue fibrosis, and osteoporosis. I certain embodiments, the Src-associated disease is cancer, and the cancer is selected from prostate cancer, breast cancer, and neuroblastoma. In other

embodiments, the Src-associated disease is cardiovascular disease, and the cardiovascular disease is selected from heart disease, cardiac hypertrophy, congesti ve heart failure, and isehemia-reperfusion injury, in some embodiments, the non-naturaHy occurring peptide used to treat the Src-associated disease comprises the sequence of SEQ ID NO 3.

[0015] Still further provided, in some embodiments of the presently-disclosed subject matter, are methods for reducing Src activity in a cell. I.n some embodiments, a method for reducing Src activity in a cell is provided that comprises contacting a. cell with an eftective amount of a peptide comprising the sequence of SEQ ID NO: 1. In some embodiments, the cell is a monocyte, a heart cell, a li er cell, a vascular cell, a breast ceil, a prostate cell, a kidney cell, a muscle cell, a brain cell, a bone cell, and/or a tumor cell, in some embodiments, the peptide of SEQ ID NO: 1, which contacts the cell, is operably linked to a cell-penetrating peptide.

[0016] Further features and advantages of the present invention will become evident to those of ordinary skill in the art after a study of the description, figures, and non-limiting examples in this document. BRIEF DESCRIPTION OF THE DRAWINGS

(0017} FIG. 1 includes images and graphs showing the effects of a peptide comprising the second cytoplasmic domain (C.D2) of the Na -ATPase on ouabain mediated Src/ER /Afct phosphorylation w here cell lines were treated with i ndicated concentration of ouabain for 1.0 minutes, where ceil !ysates were collected and analyzed by western blots for pY418 Src and total Src, phospho-ER 1/2 and total ERK.1/2, phospho- Akt and total Akt, and where the quantitative data shown are mean. ± ^■ SEM of at least three independent experiments {* p 0.. 5 compared with 0 nM control. #, p<0.05 compared with different cell lines).

[00 8] FIGS. 2A-2B include images and graphs showing the interaction of CD2 with Src. FIG. 2A is an. image showing the results of an experiment where five hundred ,ug of total cell lysate was immunoprecipitated with 10 μ¾ anti-Src antibody and immunopreeipitates were subjected to Western blot analysis of YFP and Src, FIG. 2B is an image and a graph showing the results of an experiment where five hundred μ« of total cell lysate was immunoprecipitated with 10 ,ug anti-Src antibody and analyzed for Na/K ATPase l eo-imniunoprecipitation. The values shown are mean ± SEM from at least three independent experiments. **„ p<0,0] .

[0019} FIGS, 3A-3C includes images and graphs showing CD2 as a SH2 domain !igand. FIG, 3 A includes images and a graphs showing the results of experiments where a yellow ¹ fluorescent protein { YFP) and CD2-2 expressing cells were grown up to 90% confluence, serum- starved overnight and total cell iysates were analyzed for pY4!8 Src and total Src, where a representative Western blot is shown and the data are mean ± SEM of at least three independent experiments^, p<0.05), and where, to ensure no clonal effect, CD2-1 another CD2 expressing cell line was also included. FIG. 38 includes a graph showing the resul ts of a cell spreading assay where LLC-PK.1 (untransfected), YFP and YFP-1, YFP-2 (YFP expressing control cells) and CD2-3 , CD2-2, CD2-5 (Y FP-CD2 expressing cells) were ^' harvested using trypsin and 2 x 10 ^s cells were plated in 6 cm dishes, where; at indicated time points, images of spreading cells were recorded using phase contrast microscope and spread cells are defined as cells that were not round, had extended processes, and were not phase bright, and where the quantitative data are presented as mean ± SEM of at least three independent experiments. **, p<0,01. FIG. 3C is an image showing expression of YFP and YFP-CD2 by different stable cell lines.

(QQ2wj FIGS. 4A-4C include a schematic diagram and images relating to the

phosphorylation of Y260 in CD2, FIG.4A is a schematic diagram showing C 2 sequence from Na/ -ATPase l snbunit with the tentative Src SH2 domain binding region surrounding Y260 marked in a box (SEQ ID NO: 10). FIG. 4B is an image showing the results of an experiment where five hundred pg of total cell lysate was immunoprecipitated wit 10 pg anti-Src antibody and immunopreoipi tales were subjected to Western blot analysis of tyrosine 260 phosphorylation using an anti-phosphotyrosine 260 Na/K-ATPase al antibody, and where the same membrane was stripped and probed for Y FP, FIG. 4C includes images showing the results of an experiment where LLC-P 1 ceils were grown up to 100% confluence and then serum starved overnight and treated with 100 nM ouabain for the indicated times and then western blotted by probing for pY260 l Na/K-ATPase and l Na/K-ATPase, pY4I8 Src and total Src.

(0021 j FIG. 5 is a schematic diagram showing the sequence of the unphosphorylated and phosphon lated cardiotonic steroid antagonist peptide of the presentiy-disciosed subject matter, where both the peptides are tagged with H.1V-TAT sequence at the N terminus for facilitating cell penetration (SEQ !D NOS: 4 and 3, respectively).

(002 j FIG, 6 includes images and a graphs showing the effects of developed peptides on CD2/SH2 interaction, where one unit of purified Src was incubated with, indicated concentrations of peptides for on hour and then glutath ne bead bound GST-CD2 was used to pull down available Sic, and where the bound Src was then resolved by SDS-PAGE, tKuisfmed to nitrocellulose membrane and probed with a Src specific antibody. The upper panel of FIG. 6 shows the amount of Src precipitated, whereas the lower panel of FIG. 6 shows the amount of GST bound protein used for each condition fSDS-PAGE image).

[0023) FIGS, 7A-7B include images and graphs showing the effects of pNaSH2 (SEQ ID NO: 3) on ouabain signaling. FIG. 7A includes images and a graph showing the result of an experiment where serum starved ceils were pre-incubated with or without indicated

concentrations of different peptides and then exposed to 100 nM ouabain for 10 minutes and where ceil lysates were then coilected and analyzed for pERK/ERK. FIG. 7B includes images and a graph showing the results of experiments where cells were treated with i f ⁾ ng/ml of EGF and analyzed for ERK phosphorylation.

[0024] FIG. 8 is a grap showing the effects of pNaSH2 (SEQ 03 NO: 3) o ouabain* mediated cell proliferation where ceils (20,000) were plated in triplicates in 12 well plates, all wed to grow for 24 hours and then serum starved for 24 hours, where the cells were preheated with 1 μΜ concentration of indicated peptides and then stimulated with 10 nM ouabain, and where, at indicated time points, ceil numbers were counted using a hemocytometer chamber (*„ p<0.05 compared with no treatment and #, p«X0S compared with ouabain treated (no peptide inhibition}}.

|0025j FIG. 9 includes graphs showing the effects of pNaSH2 (SEQ ID NO; 3) on ceil spreading where LLC-P l cells were pre-incubated with indicated concentrations of different peptides for one hour and the cells were harvested and plated for cell spreading as described above with reference to FIG. 3. DESCRIPTION OF EXEMPLARY EMBODIMENTS

[0026} The details of one or more embodiments of the presently-disclosed subject matter are set forth in this document. Modifications to erabodiments described in this document, and other embodiments, will be evident to those of ordinary skill in the art after a study of the information provided in this document. The information, provided in this document, and particularly the specific details of the described exemplary embodiments, is provided primarily .for clearness of understanding and no unnecessary limitations are to be understood therefrom. In case of conflict the specification of this document, including definitions, will control .

[0027] W hi le the terms used herein are belie ved to be well understood by one of ordinary skill in the art definitions are set forth herein to facilitate explanation of the presently-disclosed subject matter.

[0028] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skil l i the art to which the presently- disclosed subject matter belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used In the practice or testing of the presently- disclosed subject matter, representative methods, devices, and materials are now described.

[0029] Following long-standing patent law convention, the terms "a", "an", and "the" refer to "one or more" when used in this application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so forth.

[0030] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending upoa the desired properties sought to be obtained by the presently-disclosed subject matter,

[0031} As used herein, the term "about," when referring to a value or to an amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments 10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.

[0032] As used herein, ranges can be expressed as from "about" one particular value, and/or to "about" another particular value, it is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if i 0 and 15 are disclosed, then 11 , 12, 13, and 14 are also disclosed.

[0033] It is appreciated that the a/K-ATPase acts as a regulator of Src kinase on the cell surface by binding to and inactivating a significant amount of Src kinase (Tian, Cai et ah 2006). One of the factors in this regulation is the interaction between CD2 (second cytoplasmic domain) of Na K-ATPase and SH2 domain of Src. The SH2 domai functions in targeting Src kinase to its right binding partner in signaling pathways. In this regard, and without wishing to be bound by any particular theory or mechanism, it was believed that a SH2 domain-based inhibitor of Src kinase from CD2 of Na/K-ATPase should be capable of inhibiting Src-mediated signaling pathways specifically.

[0034] The presently-disclosed subject matter thus includes cardiotonic steroid antagonists and methods of using the same. In particular, the presently-disclosed subject matter relates to cardiotonic steroid antagonists comprising a peptid that functions as a Src SH2 domain antagonist of cardiotonic steroids, and methods of using that peptide antagonist for the treatment of Src -associated diseases, such as cancer and vascular disease. In some embodiments of the presently-disclosed subject matter, an isolated and non-naturally occurring polypeptide is provided that comprises the sequence of STNCVEGTARGlVV(pY)TG ^' D [SEQ ID MO: 1] or conservative modifications of the sequence, where pY denotes a phosphorylated tyrosine residue that improves binding to the S i2 domain of Src kinase.

{0035) The terms "polypeptide " "protein," and "peptide," which are used interchangeably herein, refer to a polymer of the 20 protein amino acids, or amino acid analo gs, regardless of its size or function. Although "protein" is often used in reference to relatively large polypeptides, and "peptide" is often used in reference to smal l polypeptides, usage of these terms in the art overlaps and varies. The term "polypeptide" as used herein refers to peptides, polypeptides, and proteins, unless otherwise noted. The terms "protein", "polypeptide" and "peptide" are used interchangeably herein when referring to a gene product. Thus, exemplary polypeptides include gene products, naturally occurring proteins, homoiogs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing.

[0036) The terms "polypeptide .fragment" or "fragment", when used in reference to a reference polypeptide, refers to a polypeptide in which amino acid residues are deleted as compared to the reference polypeptide itself, but where the remaining amino acid sequence is usually identical to the corresponding positions in the reference polypeptide. Such deletions can occur at the ammo-terminus or carboxy- terminus of the reference polypeptide, or alternatively both. [0037] A fragment can aiso be a 'functional fragment," in which case the fragment retains some or all of the acti vity of the reference polypeptide as described herein. For example, in som embodiments, a functional fragmen t of the amino acid sequence of SEQ ID NO: I retains some or all of the ab ili ty of the reference polypeptide to bind to the SH2 domain of S rc kinase.

10038) The terms "modified amino acid," "modified polypeptide " and "variant" refer to an amino acid sequence that is different from the reference polypeptide by one or more amino acids, e.g., one or more amino acid substitutions. A variant of a reference polypeptide also refers to a variant of a fragment of the reference polypeptide, for example, a fragment wherein one or more amino acid substitutions have been made relative to the reference polypeptide. A variant can also be a "functional variant," in which the variant retains some or all of the activity of the reference protei as described herein. For example, a functional variant of the amino acid sequence of SEQ ID NO; 1 retains some or all of the ability of the reference polypeptide to bind to the SH2 domain of Src kinase with a high degree of specificity.

[0039] The term functional variant includes a functional variant of a functional f agment of a reference polypeptide. The term functional variant further includes conservatively substituted variants. The term "conservatively substituted variant" refers to a peptide comprising an amino acid residue sequence that differs from a reference peptide by one or more conservative amino acid substitutions, and maintains some or all of the ac ti vi t of the reference peptide as described herein. A "conservati ve amino acid substitution" is a substitution of an amino acid residue with a functionally similar residue. Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucme, valine, leucine, or methionine for another; the substitution of one charged or polar (hydrophihc) residue for another such as between arginme and lysine, between g!utaniine and asparagine, between threonine and serine; the substitution of one basic residue such as lysine or arginine for another; or the substitution of one acidic residue, such as aspariic acid or glutamic acid for another; or the substitution of one aromatic residue, such as phenylalanine, tyrosine, or tryptophan for another. The phrase "conservatively substituted variant" also includes peptides wherein a residue is replaced with a chemical ly derivatized residue, provided that the resulting peptide maintains some or all of the acti vit of the reference peptide as described herein.

|QQ4uj The terms "isolated" or "non-naturally occurring" when used herein in the context of a nucleic acid or a poly peptide, is a nucleic acid or polypeptide that, by the hand of man, exists apart from its native environment and is therefore not a product of natur e. An isolated and/or non-natural iy occurring nucleic acid or polypeptide can exist in a purified form or can exist in a non-native environment such as, for example, in a transgenic host cell.

[00 1] In some embodiments of the presently-disclosed subject matter, an isol ated and non- naturally occurring polypeptide is provided that further comprises a ceil penetrating peptide, such that the peptide of SEQ ID NO: I can be provided as part of a fusion peptide that is capable of entering a cell and binding to the SH2 domain of Src kinase. The term "fusion protein" is intended to describe at least two polypeptides, typically from different sources, which are operatrvely linked. With regard to the polypeptides, the term "operatively linked" is intended to mean that the two polypeptides are connected in a manner such that each polypeptide can serve its intended function. Typically, the two polypeptides are cova!ently attached through peptide bonds and can be produced by standard recombinant or chemical synthesis techniques. For example, using recombinant techniques, a DNA molecule encoding a first polypeptide can be directly ligated to another DNA molecule encoding the second polypeptide, and the resultant hybrid DNA molecule can be expressed in a host cell to produce the fusion protein. The DNA molecules are generally ligated to each other in a 5' to 3' orientation such that, after ligation, the translational frame of the encoded polypeptides is not altered (i.e., the DMA molecules are ligated to each other in-frame).

[0042] Th term "cell-penetrating polypeptide ^* " is used herein to refer to polypeptides that have the ability to provide entry of a coupled peptide into a cell Exemplary cell-penetrating polypeptides that can be used in accordance with the presently-disclosed subject matter include, but are not limited to: a human immunodeficiency virus transact! vator of transcription (HIV- TAT) polypeptide (e.g., YGRKKRRQRRR (SEQ I ^' D NO: 5); Frankel, A. D., & Pabo, C. (1988), Cell, 55: 1189- 1 193; Fa elL S. _» et al., (1994) PNAS USA, 91:664-8; Becker-Hapak, M. et al. (2001 ), Methods, 24(3):247-56; Sehwarze S.R. et at (2000), Trends Cell BioL i0(7):290-5; Matsushita, K. et l. (2005), Mol. Phanii., 67(4): Π 37-44: U.S. Patent No. 6,645,501: and U.S. Patent Application Publication No. 2003/0040038); an Antennapedia homeodomam polypeptide, referred to as "penetratin" (e.g., AKiWFQNRRMKW KEN (SEQ ID NO: 6); Derossi et al., (1994), J. Bio. Chem., 269: 10444-10450); an HSV VP22 polypeptide (Elliot and O'Hare.

(1 97), Cell. 88:223-234); a polyarginme polypeptide (e.g., RRRRRRRRR; SEQ ID NO: 7); a pep-1 polypeptide ( ETWWETWWTEWSQPKKKRKV; SEQ ID NO: 8); and a transportan polypeptide (GWTLNSAGYLLGKiNL ALAALAK IL; SEQ ID NO: 9) (Stewart et al, (2008), Org. Biomol. Chem. 6, 2242-2255). In some embodiments, the cell -penetrating polypeptide is a H.1V-TAT polypeptide.

[0043] Further provided, in some embodiments of th presently-disclosed subject matter, are compositions (e.g. pharmaceutical compositions) comprising an amino acid sequence comprising at least ten amino acid residues of th sequence STNCVEGTARGIVY(pY)TGD [SEQ ID NO: 1 ] or conservati ve modifications of the sequence, where pY denotes the phosphorylated tyrosine residue to improve binding to SH2 domain of Src kinase. In some embodiments, the

composition is capable of binding to Src with an 1C50 of less than about 100 μΜ, 90 μΜ, 80 μΜ, 70 μΜ, 60 μΜ, 50 μΜ, 40 μΜ, 30 μΜ, 20 μΜ, or 3.0 μΜ. In some embodiments, the composition or amino acid sequenc is included in the composition in an amount sufficient to affect a cellular process selected from the group consisting of: antagonizing a CTS-induced proteia kinase cascade; upregalatmg a CTS induced protein kinase cascade; Src inhibition; Src stimulation; Na/ -ATPase mimic; Na/ -ATPase competitive inhibitor; Lyn inhibition; Lyn stimulation; ouabain antagonism; ouabain stimulation; ER .l/2 activation; ER 1/2 inhibition; Akt stimulation; Akt acti vation; membrane permeability by sodium ions; membrane

permeability by potassium ions.

[0044] In some embodiments, pharmaceutical compositions are provided that combine the peptides described herein with a pharmaeeufically-aeeeptable vehicle, carrier, or exctpien In some embodiments, the pharmaceutical composition is pharmacenticaily-acceptable in humans. Also, as described further below, in some embodiments, the pharmaceutical composition can be formulated as a therapeutic composition for delivery to a subject.

[0045] A pharmaceutical composition, as described herein, preferably comprises a composition that includes a pharmaceutical carrier, such as aqueous and non-aqueous sterile injection solutions that can contain antioxidants, buffers, bacteriostats, bactericidal antibiotics and solutes that render the formulation isotonic wi th the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents. The pharmaceutical compositions used can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Additionally, the formulations can be presented in unit-dose or multi-dose containers, for example seaied ampoules and vials, and can be stored in a frozen or freeze-dried or room temperature (lyophdized) condition requiring onl the addition of sterile liquid carrier immediately prior to use,

j0046j In som embodiments, solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as corn starch, gelatin, lactose, acacia, sucrose, macrocrystalline cellulose, kaolin, matmitol, diealduro phosphate, calcium carbonate, sodium chloride, or aiginic acid. Disintegrators that can be used include, but are not limited to, ttiicroerystalime cellulose, com starch, sodium starch alveolate, and aiginic acid. Tablet binders that can be used include acacia, methylcetiulose, sodium carboxymetnylcelluiose,

polyvinylpyrrolidone, hydroxypropyl methylceiliuose, sucrose, starch, and emyleellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica. Further, the solid formulations can be uneoated or they can be coated by .known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained extended action over a longer period of time. For example, glyceryl monostearate or glyceryl distearate can be employed to provide a sustained-Zextended-reiease formulation. Numerous techniques for formulating sustained release preparations are known to those of ordinary skill in the art and can be used in accordance with the present invention, including the techniques described in the following references; U.S. Pat. os, 4,8 1 ,223;

6,004.582; 5397,574; 5,419.917; 5.458,005; 5,458,887; 5.458,888; 5,472,708; 6.106,862;

6,103,263; 6,099,862; 6,099,859; 6,096,340; 6,077,541; 5,916,595; 5,837,379; 5,834,023;

5,885.616; 5,456,921 ; 5,603.956; 5.512,297; 5,399,362; 5.399,359; 5,399,358; 5.725,883;

5,773,025; 6,1 10,498; 5,952,004; 5,912,013; 5,897,876; 5,824,638; 5,464,633; 5,422, 323; and 4,839, 177; and WO 98/47491, each of which is incorporated herein by this reference. [0047] Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product: for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional techniques with pharmaceutical!y-acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl -p-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration can be suitably formulated to give controlled release of the active compound. For boccai administration, the compositions can take the form of capsules, tablets or lozenges fotrmsiaied in conventional manner.

[0048] Various liquid and powder formulations can also be prepared by conventional methods for inhalation into the lungs of the subject to be treated or for intranasal administration into the nose and sinus ca vities of a subject to be treated. For example, the compositions can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifiuoromethane,

trieMorofl.uoromeib.ane, dichlorotetrailuoroethane, carbon dioxide, or other suitable gas.

Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the desired compound and a suitable powder base such as lactose or starch.

[0049] The compositions can also be formulated as a preparation for implantation or injection. Thus, for example, the compositions can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly solubl salt). The compositions can. further be formulated as topical semi-sold ointment or cream formulations can contain a concentration of the presently-described compositions in a caif ier such as a pharmaceutical cream base. Various formulations for topics! use include drops, tinctures, lotions, creams, solutions, and ointments containing the active ingredient and various supports and vehicles. The optimal percentage of the therapeutic agent in each pharmaceutical formulation varies according to the formulation itself and the therapeutic effect desired in the specific pathologies and correlated therapeutic. In some embodiments, such ointment or cream formulations can be used for trans-dermal delivery of the pharmaceutical compositions described herein or for delivery to organs such as vagina or cervix in women.

[0056] Injectable formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethyltbrmaniide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethaool, polyois (glycerol, propylene glycol, liquid polyethylene glycol), and the like. For intravenous injections, water soluble versions of the compositions can be administered by the drip method, whereby a formulation including a pharmaceutical composition of the presently-disclosed subject matter and a physiologically-acceptable excipient is infused.

Physiologically-acceptable excipients can include, for example, 5% dextrose, 0.9% saline. Ringer's solution or other suitable excipierits. intramuscular preparations, e.g., a sterile formulation of a suitable soluble salt form of the compounds, can be dissolved and administered in a pharmaceutical excipient such as Water- for-injection, 0.9% saline, or 5% glucose solution. A suitable insol uble form of the composition can be prepared and administered as a suspension in an aqueous base or a pharmaeeutica!ly-aceeptable oil base, such as an ester of a long chain fatly acid, (e.g., ethyl oleate). [0051} In addition to the formulations described above, the compositions of the presently- disclosed subject matter can also be formulated as rectal composiiioiis, such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. Further, the compositions can also be formulated as a depot preparation by combining the compositions with suitable polymeric or hydrophobic materials (for example as aa emulsion ia an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0052] in some embodiments, the compositions described herein, in addition to including a peptide of tire presently-disclosed subject ma tter c an also include at least one additional

therapeutic agent. As used herein, the term "therapeutic agent" is used to refer to an agent that is capable of "treating" a disease, as defined herein below. In some embodiments, the therapeutic agent can comprise an agent that is useful to a treat a disease selected from the group consisting of: cancer; vascular disease; cardiovascular disease; heart disease; prostate cancer; breast cancer; neuroblastoma; cardiac hypertrophy; tissue fibrosis; congestive heart failure;

ischemia/reperfusiori injury; osteoporosis; and other Src-related diseases. In some embodiments, the additional agent is selected from the group consisting of: chemotherapeutic drug; a toxin; an immunological response modifier; an enzyme; and a radioisotope. For example, in some embodiments, other Src inhibitors, such as pNaKtide, can be used in conjunction with the pNaSH2 peptide (SEQ ID NO : I ) disclosed herein for the treatment of the above-mentioned diseases and disorders.

[0053] In some embodiments of the presently-disclosed subject matter, the therapeutic agent that is combined with a peptid of the presently-disclosed subject matter is a chemotherapeutic agent. Examples of chemotherapeutic agents that can be used in accordance with the presently- disclosed subject matter include, but are not limited to, platinum coordination compounds such as csspiaiittL earboplatm or oxalyplaiin; ta ane compounds, such as paclitaxel or docetaxel;

topoisomerase I inhibitors such as camptothecin compounds for example i inotecan or topotecan; topoisomerase II inhibitors such as anti-tumor podophyliotoxin derivatives for example etoposide or tenyposide; anti-tumor vinca alkaloids for example vinblastine, vincristine or viaorelbioe; anti-tumor nucleoside derivatives for example 5-fluorouraciL gemcitabiae or capecitabine; alkylating agents, such as nitrogen mustard or nitrosourea for example

cyclophosphamide, chlorambucil, earniustine or lomustrae; anti-tumor anthracycline derivatives fo example daunoi'ubicin, doxorubicin, idarubicin or mitoxantrone; HER2 antibodies for example trastuzomab; estrogen receptor antagonists or selective estrogen receptor modulators for example tamoxifen, toremifene, droloxifene, fasiodex or raloxifene; aromatase inhibitors, such as exeniestane, anastrozoie, letrazole and vorozoie; differentiating agents such as retinoids, vitamin D and retinoic acid metabolism blocking agents (RAMBA) for example accutaue; DNA methyl transferase inhibitors for example azacytidine; kinase inhibitors for example flavoperidol, imatinib mesylate or gefitimb famesyltransferase inhibitors; HDAC inhibitors; other inhibitors of the ubiquitin-proteasome pathway for example VELCADE® { Millennium Pharmaceuticals, Cambridge, MA); or YONDELIS® (Johnson & Johnson, New Brunswick, NJ).

[0054] Further provided, in some embodiments, of the presently-disclosed subject matter, are methods for binding a compound to the SH2 domain of Src. in some embodiments, a method for blading a compound to the SB2 domain of Src is provided that comprises contacting a compound herein to at least one SH2 domain of Src. n some embodiments, the methods include blading a compound to the SH2 domain of Src in a Src-expressing cell by contacting a compound described herein to at least one Src-expressing ceil, in some embodiments, the Src- expressing ceil is a mammalian cell such as a monocyte, heart cell liver ceil, vascular cell breast cell, prostate ceil, kidney cell, muscle cell, blood cell, brain cell, or bone cell.

j005 j Still further provided, in some embodiments of the presently-disclosed subject matter, are methods of treating a Src-associated disease in a subject in need of such treatment. In some embodiments, a method of treating a Src-associated disease is provided that comprises

administering an effective amount of a composition described herein (e.g., a peptide having the sequence of SEQ ID NO; 1) to a subject in need of such treatment. As used herein, the terms "treatment" or "treating" relate to any treatment of a condition of interest (e.g., a cancer),, including but not limited to prophylactic treatment and therapeutic treatment. As such, the terms "treatment" or "treating" include, but are not limited to: preventing a conditio of interest or the development of a condition of interest; inhibiting the progression of a condition of interest;

arresting or preventing the further deveiopment of a condition of interest; reducing the severity of a condition of interest; ameliorating or relieving symptoms associated with a condition of interest; and causing a regression of a condition of interest or one or more of the symptoms associated with a condition of interest in a subject,

[0056] As used herein, the term "subject" includes both human and animal subjects. Thus, veterinary therapeutic uses are provided in accordance with the presently disclosed subject matter. As such, the presently-disclosed subject matter provides for the treatment of mammals such as humans, as well as those mammals of importance due to being endangered, such as Siberian tigers; of economic importance, such as animals raised on farms for consumption by humans; and/or animals of social importance to humans, such as animals kepi as pets or in zoos. Examples of such animals include but are not limited to: carnivores such as cats and dogs; swine, including pigs, hogs, and wild boars; ruminants and½- ungulates such as cattle, oxen, sheep. giraffes, deer, goats, bison, and camels; and horses. Also provided is the treatmen t of birds, including the treatment of those kinds of birds that are endangered and/or kept in zoos, as well as fowl and more particularly domesticated fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, sad the like, as they are also of economic importance to humans. Thus, also provided is the treatment of livestock, including, but not limited to, domesticated swine, ruminants, ungulates, horses {including race horses), poultry, and the like.

|0057| in some embodiments, the Src-associated disease is selected from the group consisting of cancer, vascular disease, cardiovascular disease, tissue fibrosis, and osteoporosis. In some embodiments, the Src-associated disease is cardiovascular disease, and the

cardiovascular disease is selected from the group consisting of heart disease, cardiac

hypertrophy, congestive heart failure, and ischemia-reperfusion injur *.

[0058] In some embodiments, the Src-associated disease is cancer. In some embodiments, treating a cancer can include, but is not limited to, killing cancer cells, inhibiting the

development of cancer ceils, inducing apoptosis in cancer ceils, reducing the growth rate of cancer cells, reducing the incidence or number of metastases, reducing tumor size, inhibiting tumor growth, reducing the available blood suppl to a tumor or cancer cells, promoting an immune response against a tumor or cancer cells, reducing or inhibiting the initiation or progression of cancer, or increasing the lifespan of a subject with a cancer,

[0059] As used herein, the term "cancer" refers to all types of cancer or neoplasm or malignant tumors found in animals, including leukemias, carcinomas, melanoma, and sarcomas. By "leukemia" is meant broadly progressive, malignant diseases of the blood- forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in tire blood and bone marrow. Leukemia diseases include, for example, acute nonJymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocyte leukemia, adult T-ceil leukemia, aleukemic

leukeraia, a leukocyfteraic leukeraia, basophylie leukeraia, blast cell leukemia, bovine leukeraia, chronic myelocytic leukemia, leukemia cutis, embryonal leukeraia, eosinophilic leukeraia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblas c leukemia, histiocytic leukeraia, stem cell leukemia, acute monocytic leukeraia, leukopenic leukeraia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast, cell leukemia, megakaryocyte leukemia,

micromyeloblastic leukemia, monocy tic leukemia, myeloblasts leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell ieukemia, piasmaeytic Ieukemia, promyelocyte Ieukemia, Rieder cell leukemia. Schilling's ieukemia, stem cell leukemia, subleukemic leukemia, and undifferentiated cell leukemia.

[0060] The term "carcinoma" refers to a malignant new gro wth made up of epithelial cell s tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas include, for example, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocelmlare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, broochiolar carcinoma,

bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaioid carcinoma, epienno carcinoma, carcinoma epirheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosura, gelatiniforra carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellukre, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, heraatoid carcinoma, hepatocellular carcinoma, Hurthie cell carcinoma, hyaline carcinoma, hypemephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carciiioma, intraepithelial carcinoma, rorajpecher's carcinoma, Kjulchitzky-ceil carcinoma, iarge-ceJl carcinoma, lenticular carcinoma, carcinoma !enticitlare, lipomatot!s carcinoma, ivmphoepitheiiai carcinoma, carcinoma medullare, medullar ' carcinoma, melanotic carcinoma, carcinoma mo!le, mucinous carcinoma, carcinoma mtsciparum, carcinoma mucocellulare, mucoepidermoid carcmoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle ceil carcinoma, pultaceoiis carcmoma, renal ceil carcinoma of kidney, reserve cell carcinoma, carciiioma sarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet- ring cell carcinoma, carcinoma simplex, smali-celi carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle eel! carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcmoma, carcinoma te!angiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma titberosum, tuberous carcinoma, vemicous carcinoma, and carcinoma vi i iosum.

[0061] The term "sarcoma" generally refers to a tumor whic is made up of a substance like the embryonic connecti ve tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas include, for example, chondrosarcoma, fibrosarcoma, lymphosarcoma, nielanosar oraa, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma. botryoid sarcoma, chloroma sarcoma, ehorio carcinoma, embryonal sarcoma, Wilns' tumor sarcoma, endometrial sarcoma, stromal sarcoma, E ing's sarcoma, fascial sarcoma, fibroblastic sarcoma, gian t cell sarcoma, granulocytic sarcoma, Hodgkio's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immt ohlastic sarcoma of B cells, lymphoma, iramunoblastic sarcoma of T-eells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, ieukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticnJocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, and telangiectaltic sarcoma.

{0062} The term "melanoma" is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas include, for example, acral-lentiginous melanoma , ameianotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Hardiog-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma subungal melanoma, and superficial spreading melanoma.

[0063] Additional cancers include, for example, Hodgkio's Disease, Non-Hodgkin's

Lymphoma, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobidinemia, small-ceil lung tumors, primar brain tumors, stomach cancer, colon cancer, malignant pancreatic insulanoma, malignant carcinoid, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, endometrial cancer, and adrenal cortical cancer. In some embodiments, the cancer is selected from the group consisting of prostate cancer, breast cancer, and neuroblastoma.

[0064] For administration of a therapeutic composition as disclosed herein, conventional methods of extrapolating human dosage based on closes administered to a murine animal model can be carried out using the conversion factor for converting the mouse dosage to human dosage: Dose Human per kg ^:::: Dos Mouse per kg * 12 (Freireieh, et ah, ( 1 66) Cancer Chemother Rep. 50: 21 -244). Doses can also be gi ven in milligrams per square meter of body surface area because th s method rather than body weight achieves a good correlation to certain metabolic and excretionary functions. Moreover, body surface area can be used as a common denominator for drug dosage in adults and children as well as in different animal species as described by Freireieh, et al. (Freireieh et ah, { 1966) Caacer Chemother Rep. 50:21 -244). Briefly, to express a mg kg dose in any given species as the equivalent mg/sq m dose, multiply the dose by tlie appropriate kg factor. In an adult human, 100 mg/kg is equivalent to 100 mg/kg x. 37 kg ^' sq m ^~ 3700 mg/m2.

[0065] Suitable methods for administering a therapeutic composition in accordance with, the methods of the presently-disclosed subject matter include, but are not burned to, systemic administration, parenteral administration (including intravascular, intramuscular, and/or intraarterial administration), oral delivery, buccal delivery, rectal delivery, subcutaneous administration, intraperitoneal administration, inhalation, dermal ly (e.g., topical application), intratracheal installation, surgical implantation, transdermal delivery, local injection, intranasal delivery, and hyper-velocity injection/bombardment. Where applicable, continuous infusion can enhance drug accumulation at a target site (see, e.g., U.S. Patent No. 6,180,082). In some embodiments of the therapeutic methods described herein, the therapeutic compositions are administered orally, intravenously, intranasaliy. or intraperitoneal!}' to thereby treat a disease or disorder.

[0066] Regardless of the route of administration, the compositions of the presently-disclosed subject matter typically not only include an effective amount of a therapeutic agent, but are typically administered in amount effective to achieve the desired response. As such, the term "effective amount" is used ^' herein to refer to an amount of the therapeutic composition (e.g., a peptide of SEQ ID NO: 1 and a pharmaceutically vehicle, carrier, or excipient) sufficient to produce a measurable biological response (e.g., an increase in Src inhibition). Actual dosage levels of active ingredients in a therapeutic composition of the present invention can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular subject and/or application. Of course, the effective amount in any particular case will depend upon a variety of factors including the acti vity of the

therapeutic composition, formulation, t he route of administration, combination with other drugs or treatments, severity of the condition being treated, and the physical condition and prior medical history of the subject being treated. Preferably, a minimal dose is administered, and the dose is escalated in the absence of dose-limiting toxicit to a minimally effective amount.

Determination and adjustment of a therapeutically effective dose, as well as evaluation of when and how to make such adjustments, are known to those of ordinary skill in the art.

[006?] For additional guidance regarding formulation and dose, see U.S. Patent Nos.

5,326,902; 5,234,933; PCX International Publication No. WO 93/25521 ; Berkow et al, (1997) Hie Merck Manual of Medical Information, Home ed. Merck Research Laboratories,

Whitehouse Station, New Jersey; Goodman et al., ( 1996) Goodman & Oilman's the

Pharmacological Basis of Therapeutics, 9th ed. McGraw-Hill Health Professions Di vision, New York; Ebadi, (1 98) CR.C Desk Reference of Clinical Pharmacology. CRC Press, Boca Raton, Florida; Katzung, (2001 ) Basic & Clinical Pharmacology, 8th ed. Lange Medical

Books/McGraw-Hill Medical Pub. Division, New York; Remington et al., (1 75) Remington's Pharmaceutical Sciences, 15th ed. Mack Pub. Co., Easton, Pennsylvania; and Speight et al., (1997) Avery's Drag Treatment: A Guide to the Properties, Choice, Therapeutic Use and Economic Value of Drugs in Disease Management, 4th ed. Adis International. Auckland/

Philadelphia; Duch et al., (1998) Toxicol Lett 100-101:255-263.

j0068| By virtue of the binding affinity of the peptides descr ibed herein to the SH2 domain of Src, in some embodiments,, methods for reducing Src activity in a cell can also be provided that comprise the ste of contactin a cell with an effective amount of a Sre-inhibiting peptide described herein (e.g., a peptide of SEQ ID NO: I). In some embodiments, the ceil is selected trom the group consisting of a monocyte, a heart ceil, a liver cell a vascular cell, a breast cell, a prostate cell, a kidney cell, a muscle cell, a brain cell, and a tumor ceil, in some embodiments, embodiments, by contacting a cell with a composition described herein, the composition affects Focal Adhesion Kinase (FAK) activity in the ceil (e.g., a tumor cell), reduces reducing tumor cell migration, kills cancer cells when the expression o a ATPase is reduced, inhibits cell growth in a tumor cell, inhibits prostate tumor cell growth, inhibits breast tumor cell growth, or affects: Src binding; Src inhibition; Src stimulation; Src function; Lyn binding: Lyn function; Lyn inhibition; ouabain antagonism; a/K-ATPase function; ERKl/2 function; FAK inhibition; membrane permeability by sodium ions; and membrane permeability by potassium ions.

[0069] Various methods known to those skilled in the art can be used to assess the foregoing effects. Furthermore, although certain embodiments of the methods disclosed herein only call for a qualitative assessment (e.g., the presence or absence of Src inhibition), other embodiments of the methods call for a quantitative assessment (e.g., an amount of Src inhibition in a subject or a cell or tissue of the subject). Such quantitativ assessments can be made, for example, using any number of methods, as will be understood by those skilled in the art.

[0070] With respect to the administration of or the contacting of a cell with the compositions described above to reduce an amount of Src activity, the terms "reduce," "reducing," or ^reduction" when used herein in referenc to Src sctivity are used to refer to any decrease or suppression in the amount or rate of Src activity. Of course, it is understood that the degree of reduction need not be absolute (i.e., the degree of inhibition, need not be a corapiete prevention of Src activity) and that intermediate levels of a reduction in Src activity are contemplated by the presently-disclosed subject matter. As such, in. some embodiments, the reduction in Sre activity can be about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%.

[0071 ) The skilled artisan will also understand thai measuring a reduction in the amount of a certain feature (e.g., Src inhibition) or an improvement in a certain feature (e.g., tumor size) in a subject is a statistical analysis. For example, an increase in. an amount of Src inhibition in a subject can be compared to control level of Src activity, and an Src inhibition of less than or equal to the control level can be indicative of a reduction in the amount of Src acti vity, as evidenced by a level of statistical significance. Statistical significance is ofteii determined by comparing two or more populations, and determining a confidence interval and/or a value. See, e.g., Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York, 1983, incorporated herein by reference in its entirety. Preferred confidence intervals of the present subject matter are 90%, 95%, 97.5%, 98%, 99%,, 99.5%, 99.9% and 99.99%, while preferred p values are 0.1 , 0,05, 0.025, 0.02, 0.01, 0.005, 0.001 , and 0.0001.

[0072] The practice of the presently-disclosed subject matter can employ, unless otherwise indicated, con ventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Molecular Cloning A Laboratory Manual ( 1989), 2nd Ed., ed. by Sambrook, Fritseh and Maniatis, eds.. Cold Spring Harbor

Laboratory Press, Chapters 16 and .17; U.S. Pat. No. 4,683,1 5; DNA Cloning, Volumes I and ΪΪ, Glover, ed., 1985; Oligonucleotid Synthesis, M. J. Gait, ed., 1984; Nucleic Acid Hybridization, D. Harass & S. J. Biggins, eds., 1984; Transcription and Translation, B. D. Haraes & S. J.

Wiggins, eels., 1984; Culture Of Animal Cells, R. 1. Preshney, Alan . Liss, Inc., 1987;

Immobilized Ceils And Enzymes, IRL Press, 1986; Perbai (1984), A Practical Guide To

Molecular Cloning; See Methods in Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells, I H, Miller and M. P. Calos, eds.. Cold Spring Harbor

Laboratory, 1987; Methods hi Enzymology, Vols. 154 and 155, Wu et al., eds., Academic Press Inc., N.Y.; Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987; Handbook Of Experimental Immunology, Volumes I-IV, D. M. Weir and C. C BlackwelL eds., 1986.

[0073) The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.

EXAMPLES

[0074) Example 1 -- Second Cytoplasmic Domain of Na K-ATPase as a Regulator of Src SH2 Domain.

[0075| The Na/K-ATPase interacts with Src kinase directl by two domain-domain interactions (Tian, Cai et. al. 2006, Ye, Li et al. 201 1). Specifically, the second cytoplasmic domain (CD2) of the Na/K-ATPase binds the Src SH2 domain and the N domain of the Na/K- ATPase binds the Src kinase domain. The binding of cardiotonic steroids, such as ouabain, disrupts the N domain/kinase domain interaction, whereas the CD2/SH2 interaction is generally constitutive. In this regard, since the CD2 binds the Src SH2 domain and the SH2 domain functions in targeting Src kinase to specific signaling complexes, it was believed that ectopicall; expressed CD2 would act as a dominant-negative mutant of the a K~ATPase/Src receptor complex in cells and thereby inhibit ouabain-mediated cell signaling. To test that belief, CD2 was expressed in LLC-P I cells as a yellow fluorescent protein ( YFF) fused protein and a YFF expressing cell l ine was used as a. control. From these experiments, it was demonstrated that CD2 could inhibit ouabain-mediated protein phosphorylation in cells (FIG. 1) by binding to Src kinase (FIG. 2A) and preventing Src Kinase from bein targeted to the ^' Na -ATPase (FIG. 2B). Those studies confirmed the validity of CD2/SH2 interaction, and also indicated a role for CD2-mediated regulation of Src kinase through the Src SH2 domain in cellular physiology.

[0076] To further clarify the function of CD2 as a SH2 domain inhibitor, whether CD2 acts as a SH2 domai ligand in cells was next examined. It is appreciated that SH2 domain ligands can increase the basal Src activity by displacing its intra-molecular regulation (Liu, Brodeur et at. 1993, Yadav and Miller 2007). in this regard, if CD2 behaves like a SH2 domain ligand in cells, it should increase basal Src activity measured as Y 18 phosphorylation. As depicted in FIG. 3 A, it was determined that CD2 expression does increase basal Src activity in this manner as compared with a control cell line.

[0077] It is also appreciated that cell spreading is a process by which cells attach in their normal tissue microenvironment, and studies have shown that eel! spreading is dependent on tht SH2 domain of Src kinase (Kaplan, S edlow et al. 1995). In this regard, it was next investigated whether CD2 can regulate cell spreading by acting as a SH2 domain inhibitor in cells. Upon analysis of the results from those experiments, it was determined that expression of CD2 was capable of inhibiting Src-mediated cell spreading (FIG. 3B) in a dose-dependent manner (FIG. 3C). Thus, th above studies confirmed the role of CD2 as SH2 domain-specific ouabain/cardiotonic steroid aniagoni st,

[0078] Example 2 --- Development of Peptide Antagonist for D

nteraction.

|007 ] In view of the foregoing fi ndings, experimen ts were then undertaken to develop a highly specific peptide antagonist for disrupting the CD2/SH2 interactio in order to inhibit the cardiotonic steroid-mediated signaling in cells. Src SH2 domains have been observed to display a preference in binding phosphorylated tyrosine residues. As shown in FIG. 4A, CD2 from Na/K-ATPase al. subunit (mammalian; S.EQ ID NO:) contains only a single tyrosine at position 260 (in unmodified Na/K-ATPase), so an experimeiii was performed to determine if that tyrosine could be phosphorylated in CD2 expressing cells. As depicted in FIG. 4B, CD2 was capable of being phosphorylated when it was expressed in ceils. FIG. 4C further shows that in normal LLOPK I cells, tyrosine 260 of full length Na K-ATPase was phosphorylated. Moreover, that phosphorylation could be stimulated by ouabain, as ouabain increased the phosphorylation in a time-dependent manner. These findings thus indicated that the tyrosine 260 can indeed be phosphorylated in normal cells and may be an important factor for SH2 domain binding in the target peptide, it is also important to note that non-phosphorylaied CD2 could also hind Src SH2, as was previously demonstrated, with high affinity (Tian, Cas ei al. 2006, Ye, Li et ai. 201 1). Thus, it was conceivable thai pY260 CD2 could have a much higher binding affinity to Src SH2, snaking the CD2-derived phospho-peptide a more effective Src SH2 inhibitor as well as a better antagonist of cardiotonic steroids.

fOOSOj £xamp.ie ,3.-.Affimty. of Peptide. Anta^ I ^' QQSlj It was previously demonstrated that a peptid deri ved from CD2 called CD2C2 (see, e.g., SEQ D NO; 1 in PCT Application No. PCT7US201 1/021 130, which is incorporated herein by reference} is an effective ouabain antagonist when assayed using a reconstituted in vitro system. In view of the abo ve new findings and th previous information regarding CD2C2, experiments were subsequently undertaken to assess whether the same peptide wit Y260 being phospborylated (see SEQ ID NO: I of t he present application) has a higher affi nity than CD2C2 (see SEQ ID NO: 2 of the present application). Briefly, to perform these experimeiits, and in order to make the peptide cell membrane permeable, the peptide of SEQ ID NO: 1 was attached to a TAT tag as done previously with other Na K- ATPase-derived peptides (Li, Cai et al. 2009). The new peptide was designated p aSH2 (SEQ ID NO: 3). To compare and contrast, CD2C2 was also synthesized with the same TAT ^" tag, and was designated as NaSH2 (SEQ ID NO: 4} to indicate that the peptide was not phospborylated at Y26Q, The sequences and names of these peptides are shown in FIG. 5.

[0082] To assess the effectiveness of the phosphorylated peptide (pNaSH2) versus the nan- phosphorylated peptide (NaSH2), in vitro peptide inhibition assays were then performed.

Briefly, purified human recombinant Src was incubated with different concentrations of both the peptides for 30 min. Glutathione head hound GST - CD2 was then added to the reaction and incubated for 1 hour. The GST pull down pellets were then analyzed for hound Src using an anti- Src antibody. As shown in FIG, 6, pNaSI I2 was more potent and effective than NaSH2 in blocking CD2/Src interaction.

[0083] According to the previous datasei, if pNaSH2 is capable of blocking CD2/SM2 interaction it should aiso antagonize ouabain-raediated ERK phosphorylation in cells. In this regard, LLC-P i ceils were then pretreated with either 0,5 μΜ of NaSH2 or pNaSH2 and 1 μΜ pNaKtide (positive control) for I hour. The cells were then stimulated with 100 »M ouabain ^" for 10 minutes and assayed for phosphory!ated ER by Western blot. As shown in FIG. 7A, pNaSH2„ but not Na$H2, completely abolished ouabain-mduced ERK phosphorylation. In con trast, none of the peptides were able to inhibit EGF mediated ERK phosphorylation (FIG. 71$), indicating thai the effect of pNaSH2 was specific to the ouaba -mediated signaling pathway. Ouabain can also stimulate cel l proliferation of LLC-FK3 cells at very low

concentrations (Tian, Li et al. 2009), Therefore, as an ouabain antagonist, it was believed that pNaSH2 should be able to inhibit ouabain-mediated cell prol iferation. As depicted in FIG- 8, pNaSH2 did in fact inhibit ouabain-induced. cell proliferation, while NaSH2 was ineffective at the concentration utilized. Furthermore, to assess whether p aS 2 was effective in acting as a Src SH2 inhibitor, its effect on cell spreading was also measured. As depicted in FIG. 9, pNaSH2 was more effective in the inhibition of cell spreading.

[0084] Taken together the above studies indicate that presence of a phosphor iated tyrosine increases the effectiveness of the CD2-derived peptide by making it a more efficient and specific ouabain antagonist as well as a Src SH2 inhibitor. Those properties of p aSH2 (the dual functionalities) and high effectiveness of pNaS.H2 make the peptide unique in comparison with other developed SH2 inhibitors reported in the literature, in vi ro competition analyses indicated that pNaSH2 has an iC¾i of about 0.5 μ ^' in comparison t about 6.5 μ ^' with the best SH2 inhibitory peptide pYEEl discovered so far ( raskouskaya, Dtiodu et al, 2013), Further, it was believed that the above experiments show for the first time that pNaSH2 is as effective as SH2 inhibitors in cells at concentration of 1. μΜ. Finally, it was believed that in light of those properties, the practical, usefulness of pNaSB2, in comparison to NaS.H2, was greater even though both may block ouabain signaling and act as a SH2 inhibitor. That increased effectiveness made it possibl for the use of pNaSH2 as an experimental tool as well as for further development of new therapeutics.

|0085] Throughout this document, various references are mentioned. All such references are incorporated herein by reference, including the references set forth in the following list;

REFERENCES

1. Bagrov, A. Y., J. I. Shapiro and O. V. Fedorova (2009), "Endogenous cardiotonic

steroids: physiology, pharmacology, and novel therapeutic targets," Pharmacol Re

61 (1 ): 9-38.

2. Boggon, T. J. and M. J. Eck (2004). "Structure and regulation of Src family kinases." Oncogene 23(48): 7918-7927.

3. Boien, J. B., A. VeUlette, A. M. Schwartz, V. DeSeau and N, Rosen (1 87). "Activation o p60e~src protein kinase activity in human colon carcinoma." Proc Nail. Acad Sci U S

A 84(8): 2251-2255.

4. Bromann, P. A., H. Korkaya and S. A. Courtneidge (2004). "Hie interplay between Src family kinases and receptor tyrosine kinases." Oncogene 23(48): 7957-7968.

5. Brunton, V. G. _; E. Avizienyte, V. Fincham, B. Serrels, C. A. eicalf, 3rd, T. K.

Sawyer and M. C. Frame (2005). "Identification of Src-specific phosphorylation site on focal adhesion kinase; dissection of the role of Src SR2 and catalytic functions and then' consequences for tumor cell behavior." Cancer Res 65(4): 1 35-1342.

6. Kaplan, K. B., J, R. Swedlow, D. <), Morgan and H. E. Varmus ( 1995). "c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kmase-indepenclerst mechanism." Genes Dev 9( 12): 1505- 1 17.

7. raskouskaya, D., E. Duoclii, C. C. Arpin and P, T. Gunning (2013). "Progress towards the development of SH2 domain inhibitors." Chem Soc Rev 42(8): 3337-3370. Li, Z.„ T. Cai, J. Xiao, J. X. Xie, X. Zhao, L. Liu, J. I. Shapiro and £ ^" . Xie (2009).

" aKlide, a a-'K-ATPase-derived peptide Src inhibitor, antagonizes oimbain-actrvate signal transduction in cultured cells," J Biol Chem 284(31 ): 21066-21076, Liu, .X., S. R, Brodeur, G. Gish, Z. Songyang, L. C. Cantley, A, P. Laudano and T. Pawson (1993), "Regulation of c-Src tyrosine kinase activity by the Src SH2 domain."

Oncogene 8(5): 1 1 19-1 126. Prassas, i. and E. P, Diamandis (2008), "Novel therapeutic applications of cardiac glycosides." Nat Rev Drug Discov 7(1 1 ): 926-935, Shvartsman, D. E., J. C. Donaldson, B. Diaz. O. Gutman, G. S. Martin and Y. 1. Henis (2007), "Src kinase activity and SH2 domain regulate the dynamics of Src association with lipid and protein targets." J Cell Biol 178(4): 675-686. Songyang, Z. and L C. Cantley (2004). "ZIP codes for deli ering SH2 domains." Cell 1 1 (2 Suppl): S41-43, 42 p following S48, Songyang, Z., S. E, Shoelson, M. Cliaudhuri, G. Gish, T. Pawson. W. G. Haser, F. King. T. Roberts, S. Ratnofsky, R. .1, Lechleider and et ai. (1993). "SH2 domains recognize specific phosphopeptide sequences." Cell 72(5): 767-778. Tian, J,, T. Cai, Z. Yuan, H. Wang, L. Liu, M.. Haas, E. Maksiraova, X. Y. Huang and Z. J. Xie (2006). "Binding of Src to Na- /K+~ATPase forms a functional signaling complex." Mol Biol Cell 17(1): 317-326. Tian, L, X. Li, M. Liang, L. Liu, J. X. Xie, Q. Ye, P. Kometiani, M. Tillekeratne, R. Jin and Z. Xie (2009). "Changes in sodium pump expression dictate the effects of ouabain on cell growth." J Biol Chem 284(22): 14921 -14929. Xie, Z. and T. Cai (2003). "Na+- - ~ATPase-mediated signal transduction: from protein interaction to cellular function." Mol interv 3(3): 157-168. Yadav, S. S. and W. T. Miller (2007). "Cooperative activation of Src family kinases by SH3 and SH2 ligands." Cancer Lett 257(1): 1 16-523. 18. Ye, Q., Z. Li, J. Tian, J. X. Xie, L. Liu and Z. Xie (20 Π). "Identification of a potential receptor that couples ion transport to protein kinase activity." J Biol Chem 286(8): 6225- 6232.

1 . International Patent Application Publication No. WO 201 1/088210, filed January 13, 20ί ί , and entitled "Materials and Methods Related to Sodium/Potassium Adenosine Triphosphatase and Src."

[0086] It will be understood that various details of the presently disclosed subject matter can be changed without departing from the scope of the subject matter disclosed herein. Furthermore, the foregoing description is for the purpose of il lustration only, and not for the purpose of limitation.